These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 28765915)

  • 1. miR-93 and PTEN: Key regulators of doxorubicin-resistance and EMT in breast cancer.
    Chu S; Liu G; Xia P; Chen G; Shi F; Yi T; Zhou H
    Oncol Rep; 2017 Oct; 38(4):2401-2407. PubMed ID: 28765915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-200b regulates epithelial-mesenchymal transition of chemo-resistant breast cancer cells by targeting FN1.
    Yang X; Hu Q; Hu LX; Lin XR; Liu JQ; Lin X; Dinglin XX; Zeng JY; Hu H; Luo ML; Yao HR
    Discov Med; 2017 Sep; 24(131):75-85. PubMed ID: 28972876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-κB signaling pathway in breast cancer.
    Xie M; Fu Z; Cao J; Liu Y; Wu J; Li Q; Chen Y
    Biomed Pharmacother; 2018 Jun; 102():286-294. PubMed ID: 29567542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-222 induces Adriamycin resistance in breast cancer through PTEN/Akt/p27
    Wang DD; Yang SJ; Chen X; Shen HY; Luo LJ; Zhang XH; Zhong SL; Zhao JH; Tang JH
    Tumour Biol; 2016 Nov; 37(11):15315-15324. PubMed ID: 27699665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway.
    Shen H; Wang D; Li L; Yang S; Chen X; Zhou S; Zhong S; Zhao J; Tang J
    Gene; 2017 Jan; 596():110-118. PubMed ID: 27746366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
    De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
    Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-381 inhibited breast cancer cells proliferation, epithelial-to-mesenchymal transition and metastasis by targeting CXCR4.
    Xue Y; Xu W; Zhao W; Wang W; Zhang D; Wu P
    Biomed Pharmacother; 2017 Feb; 86():426-433. PubMed ID: 28012397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells.
    Li H; Zhang P; Sun X; Sun Y; Shi C; Liu H; Liu X
    Int J Oncol; 2015 Oct; 47(4):1379-92. PubMed ID: 26323677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-137 alleviates doxorubicin resistance in breast cancer through inhibition of epithelial-mesenchymal transition by targeting DUSP4.
    Du F; Yu L; Wu Y; Wang S; Yao J; Zheng X; Xie S; Zhang S; Lu X; Liu Y; Chen W
    Cell Death Dis; 2019 Dec; 10(12):922. PubMed ID: 31801953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased fucosylation has a pivotal role in multidrug resistance of breast cancer cells through miR-224-3p targeting FUT4.
    Feng X; Zhao L; Gao S; Song X; Dong W; Zhao Y; Zhou H; Cheng L; Miao X; Jia L
    Gene; 2016 Mar; 578(2):232-41. PubMed ID: 26701615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells.
    Zhong S; Li W; Chen Z; Xu J; Zhao J
    Gene; 2013 Nov; 531(1):8-14. PubMed ID: 23994196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer.
    Sun L; Burnett J; Gasparyan M; Xu F; Jiang H; Lin CC; Myers I; Korkaya H; Liu Y; Connarn J; He H; Zhang N; Wicha MS; Sun D
    Oncotarget; 2016 Aug; 7(32):51408-51422. PubMed ID: 27285982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-375 inhibits cancer stem cell phenotype and tamoxifen resistance by degrading HOXB3 in human ER-positive breast cancer.
    Fu H; Fu L; Xie C; Zuo WS; Liu YS; Zheng MZ; Yu JM
    Oncol Rep; 2017 Feb; 37(2):1093-1099. PubMed ID: 28075453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-21 modulates chemosensitivity of breast cancer cells to doxorubicin by targeting PTEN.
    Wang ZX; Lu BB; Wang H; Cheng ZX; Yin YM
    Arch Med Res; 2011 May; 42(4):281-90. PubMed ID: 21820606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of miR-125b-mitochondria-caspase-3 pathway in doxorubicin resistance and therapy in human breast cancer.
    Xie X; Hu Y; Xu L; Fu Y; Tu J; Zhao H; Zhang S; Hong R; Gu X
    Tumour Biol; 2015 Sep; 36(9):7185-94. PubMed ID: 25894378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling.
    Chen Y; Sun Y; Chen L; Xu X; Zhang X; Wang B; Min L; Liu W
    Mol Med Rep; 2013 May; 7(5):1579-84. PubMed ID: 23546450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-497 inhibits epithelial mesenchymal transition in breast carcinoma by targeting Slug.
    Wu Z; Li X; Cai X; Huang C; Zheng M
    Tumour Biol; 2016 Jun; 37(6):7939-50. PubMed ID: 26700673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiRNA-21 induces epithelial to mesenchymal transition and gemcitabine resistance via the PTEN/AKT pathway in breast cancer.
    Wu ZH; Tao ZH; Zhang J; Li T; Ni C; Xie J; Zhang JF; Hu XC
    Tumour Biol; 2016 Jun; 37(6):7245-54. PubMed ID: 26666820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-135b-5p enhances doxorubicin-sensitivity of breast cancer cells through targeting anterior gradient 2.
    Zhang Y; Xia F; Zhang F; Cui Y; Wang Q; Liu H; Wu Y
    J Exp Clin Cancer Res; 2019 Jan; 38(1):26. PubMed ID: 30665445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic analysis of gene expression pattern in has-miR-760 overexpressed resistance of the MCF-7 human breast cancer cell to doxorubicin.
    Lv J; Fu Z; Shi M; Xia K; Ji C; Xu P; Lv M; Pan B; Dai L; Xie H
    Biomed Pharmacother; 2015 Feb; 69():162-9. PubMed ID: 25661353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.